WorkThe story, in brief
Reid Hoffman is leaving Microsoft’s board to go ‘founder mode’ with startup Manus
Reid Hoffman just left Microsoft's board. Here's why an AI drug discovery startup matters more to him than a $3T company.
The KeyNews take
Why it matters
A top-tier operator is betting his time and reputation on AI-driven drug discovery over board seats. This signals where serious founders see the next wave of AI value creation — and which established positions they're willing to abandon for it.
The key facts
4 to knowReid Hoffman departing Microsoft board after decade
Hoffman shifting focus to AI drug discovery startup Manus
Signal of founder-led AI startups attracting elite talent from Fortune 500 boards
Drug discovery emerging as high-conviction AI application space
Go to the source
TechCrunch Venturetechcrunch.com
Publisher excerpt: After a very profitable decade on Microsoft's board, Reid Hoffman is stepping down to focus on his AI drug discovery startup Manus.